William New

William New

Obama 2012 Budget Proposal Reduces Exclusivity For Biologics

Shortly after passage last year of the US healthcare reform act called for a regulatory pathway to bring follow-on biologic drugs, or biosimilars, to market with 12 years of data exclusivity for brand-name producers, the Obama administration has proposed to reduce that time to its original 7 years, according to sources. The move, contained in the 2012 budget proposal, is expected to allow lower priced generic versions of drugs to enter the market sooner, a benefit to consumers.

Pharma Backs Calls For Extension Of TRIPS Deadline For Least-Developed Countries

Developed country pharmaceutical companies today announced their support for an extension of the deadline for poor countries to comply with a global trade agreement on intellectual property rights that would significantly raise their obligations to protect IP. The extension idea has been proposed by the United Kingdom government in a new trade strategy document.

New White House IP Advisory Committees Elevate IP Enforcement To Highest Level

US President Barack Obama this week used an executive order to create two government advisory committees on intellectual property rights enforcement. The committees put IP rights at the highest interagency level possible and have the stated aim of promoting innovation through the protection of such rights.